Candida auris : An Overview of the Emerging Drug-Resistant Fungal Infection
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Candida auris is an invasive fungal pathogen that has been recognized globally as a serious health threat due to its extensive innate and acquired resistance to antifungal drugs. A growing number of emerging cases of C. auris have been reported with resistance to the standard antifungal treatments including azoles, echinocandins, and polyenes, making it difficult to treat. Unlike other Candida species, C. auris is challenging to diagnose using the standard laboratory methods and are typically prone to misidentification, resulting in inappropriate management. Consequently, C. auris infections have spread globally. The Centers for Disease Control and Prevention data showed that clinical cases of C. auris increased from 329 in 2018 to 1,012 in 2021. The incidence and prevalence of this invasive fungal infection are high in immunocompromised and hospitalized patients. Patients who had an organ transplant, are on immunosuppressive agents, are diabetic, recent antibiotic use, catheter use, and prolonged hospital or nursing homestays are vulnerable to C. auris infections. C. auris is rapidly spreading across healthcare settings globally and monitoring of its virulence as well as devising appropriate treatment approaches are thus highly required.
Abstract
Candida auris is an invasive fungal pathogen that has been recognized globally as a serious health threat due to its extensive innate and acquired resistance to antifungal drugs. A growing number of emerging cases of C. auris have been reported with resistance to the standard antifungal treatments including azoles, echinocandins, and polyenes, making it difficult to treat. Unlike other Candida species, C. auris is challenging to diagnose using the standard laboratory methods and are typically prone to misidentification, resulting in inappropriate management. Consequently, C. auris infections have spread globally. The Centers for Disease Control and Prevention data showed that clinical cases of C. auris increased from 329 in 2018 to 1,012 in 2021. The incidence and prevalence of this invasive fungal infection are high in immunocompromised and hospitalized patients. Patients who had an organ transplant, are on immunosuppressive agents, are diabetic, recent antibiotic use, catheter use, and prolonged hospital or nursing homestays are vulnerable to C. auris infections. C. auris is rapidly spreading across healthcare settings globally and monitoring of its virulence as well as devising appropriate treatment approaches are thus highly required.
참고문헌 (39)
- Pharkjaksu S, "Immunopathogenesis of emerging Candida auris and Candida haemulonii strains", J Fungi(Basel), 7, pp.725~ (2021)
- Satoh K, "Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital", Microbiol Immunol, 53, pp.41~44 (2009)
- Bravo Ruiz G, "What do we know about the biology of the emerging fungal pathogen of humans Candida auris?", Microbiol Res, 242, pp.126621~ (2021)
- Spivak ES, "Candida auris : an emerging fungal pathogen", J Clin Microbiol, 56, pp.e01588-17~ (2018)
- Du H, "Candida auris : Epidemiology, biology, antifungal resistance, and virulence", PLoS Pathog, 16, pp.e1008921~ (2020)
- Sarma S, "Current perspective on emergence, diagnosis and drug resistance in Candida auris", Infect Drug Resist, 10, pp.155~165 (2017)
- Desoubeaux G, "Overview about Candida auris : What’s up 12 years after its first description?", J Mycol Med, 32, pp.101248~ (2022)
- Eckbo EJ, "First reported outbreak of the emerging pathogen Candida auris in Canada", Am J Infect Control, 49, pp.804~807 (2021)
- Chow NA, "Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA : a molecular epidemiological survey", Lancet Infect Dis, 18, pp.1377~1384 (2018)
- Abe M, "Potency of gastrointestinal colonization and virulence of Candida auris in a murine endogenous candidiasis", PLoS One, 15, pp.e0243223~ (2020)
- Adams E, "Candida auris in healthcare facilities, New York, USA, 2013-2017", Emerg Infect Dis, 24, pp.1816~1824 (2018)
- de Jong AW, "Nanopore genome Sequencing and variant analysis of the susceptible Candida auris strain L1537", 2020, Salvador, Brazil, 2021, pp.186, 883~887
- Brandt ME, "Recent taxonomic developments with Candida and other opportunistic yeasts", Curr Fungal Infect Rep, 6, pp.170~177 (2012)
- Sardi JCO, "Candida species : current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options", J Med Microbiol, 62, pp.10~24 (2013)
- Eggimann P, "Epidemiology of Candida species infections in critically ill nonimmunosuppressed patients", Lancet Infect Dis, 3, pp.685~702 (2003)
- Fasciana T, "Candida auris: An overview of how to screen, detect, test and control this emerging pathogen", Antibiotics(Basel), 9, pp.778~ (2020)
- Silva S, "Candida glabrata, Candida parapsilosis and Candida tropicalis : biology, epidemiology, pathogenicity and antifungal resistance", FEMS Microbiol Rev, 36, pp.288~305 (2012)
- "Candida auris: General information about Candida auris" (2021)[URL]
- "Tracking Candida auris" (2022)[URL]
- "Candida auris: Antifungal susceptibility testing and interpretation" (2020)[URL]
- Chowdhary A, "A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates(2009-17)in India : role of the ERG11and FKS1 genes in azole and echinocandin resistance", J Antimicrob Chemother, 73, pp.891~899 (2018)
- Forsberg K, "Candida auris : The recent emergence of a multidrug-resistant fungal pathogen", Med Mycol, 57, pp.1~12 (2019)
- Zamith-Miranda D, "Multi-omics signature of Candida auris, an emerging and multidrugresistant pathogen", mSystems, 4, pp.e00257~19 (2019)
- Ciurea CN, "Candida auris and other phylogenetically related species-a mini-review of the literature", Germs, 11, pp.441~448 (2021)
- "The superbug Candida auris is giving rise to warnings - and big questions" (2019)[URL]
- Casadevall A, "On the emergence of Candida auris : Climate change, azoles, swamps, and birds", mBio, 10, pp.e01397-19~ (2019)
- Cortegiani A, "Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris", J Intensive Care, 6, pp.69~ (2018)
- Chatterjee S, "Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris", BMC Genomics, 16, pp.686~ (2015)
- Allert S, "From environmental adaptation to host survival : Attributes that mediate pathogenicity of Candida auris", Virulence, 13, pp.191~214 (2022)
- Finkel JS, "Genetic control of Candida albicans biofilm development", Nat Rev Microbiol, 9, pp.109~118 (2011)
- Pappas PG, "Clinical practice guideline for the management of candidiasis : 2016 update by the Infectious Diseases Society of America", Clin Infect Dis, 62, pp.e1~50 (2016)
- "Treatment and management of infections and colonization" (2021)[URL]
- Osei Sekyere J, "Candida auris : A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen", MicrobiologyOpen, 8, pp.e00901~ (2019)
- "Identification of Candida auris" (2020)[URL]
- Rhodes J, "Global epidemiology of emerging Candida auris", Curr Opin Microbiol, 52, pp.84~89 (2019)
- Johnson CJ, "Emerging fungal pathogen Candida auris evades neutrophil attack", mBio, 9, pp.e01403-18~ (2018)
- Maslo C, "The efficacy of pulsed-xenon ultraviolet light technology on Candida auris", BMC Infect Dis, 19, pp.540~ (2019)
- Caceres DH, "Candida auris: A review of recommendations for detection and control in healthcare settings", J Fungi(Basel), 5, pp.111~ (2019)